Gossamer Bio, Inc.
For the period ended Sep 30, 2026. Filed Nov 10, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Nov 10, 2026
GOSS$11.28+6.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Balance Sheets
(in thousands, except share and par value amounts)
| September 30, 2026 | December 31, 2025 | |
|---|---|---|
| ASSETS · (unaudited) | ||
| Current assets | ||
| Cash and cash equivalents | $51,189 | $37,732 |
| Marketable securities | — | 99,200 |
| Receivable from contracts with collaborators | — | 12,227 |
| Prepaid expenses and other current assets | 9,237 | 18,485 |
| Total current assets | 60,426 | 167,644 |
| Property and equipment, net | 51 | 64 |
| Operating lease right-of-use assets | 3,436 | 4,133 |
| Other assets | 424 | 408 |
| Total assets | $64,337 | $172,249 |
| LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT) | ||
| Current liabilities | ||
| Accounts payable | $1,470 | $5,959 |
| Accrued research and development expenses | 8,082 | 21,662 |
| Current contract liabilities | — | 19,987 |
| Current convertible senior notes | 37,150 | — |
| Embedded derivative liability at fair value | 37,369 | — |
| Accrued expenses and other current liabilities | 15,874 | 15,827 |
| Total current liabilities | 99,945 | 63,435 |
| Long-term convertible senior notes | — | 198,508 |
| Operating lease liabilities - long-term | 2,695 | 3,460 |
| Long-term contract liabilities | — | 29,606 |
| Long-term warrant liability at fair value | 84,492 | — |
| Total liabilities | 187,132 | 295,009 |
| Commitments and contingencies (Note 9) | ||
| Stockholders' equity (deficit) | ||
| Common stock, $0.0001 par value; 50,000,000 shares authorized as of September 30, 2026 and 8,750,000 shares authorized as of December 31, 2025 (after giving effect to the reverse stock split); 6,116,390 shares issued and outstanding as of September 30, 2026, and 2,920,964 shares issued and outstanding as of December 31, 2025 | 1 | — |
| Additional paid-in capital | 1,397,593 | 1,321,327 |
| Accumulated deficit | (1,516,774) | (1,438,938) |
| Accumulated other comprehensive loss | (3,615) | (5,149) |
| Total stockholders' deficit | (122,795) | (122,760) |
| Total liabilities and stockholders' deficit | $64,337 | $172,249 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.